A study confirms the effectiveness of “Sputnik V” against new strains of the Corona virus

The research methodology was based on evaluating the neutralizing ability of antibodies using a live virus, which allowed obtaining data with very high reliability as a “gold standard” for the efficiency of the vaccine.

In the context of the study, the BHA of human blood serum after vaccination was compared with the “Sputnik V” vaccine on samples of coronavirus strains scattered around the world, including the new mutated strains.

The study confirmed that the antibiotics that were present in the recipients of the “Sputnik V” vaccine were able to neutralize corona viruses from new strains, including “Alpha B.1.1.7), which appeared for the first time in Britain, and the “Beta” strain (Beta B.1.351). ), which first appeared in South Africa, the “Gamma P.1” strain, which first appeared in Brazil, the “Delta” strain (Delta B. 1.617.2) and the “B.1.617.3) strain For the first time in India, in addition to the strains (B.1.1.141) and (B.1.1.317) identified in Moscow.

The results of the study indicated that “Sputnik V” maintains its protective properties against new strains.

The results showed that the decrease in the level of inactivating activity of “Sputnik V” for a number of strains was significantly lower compared to the data published by other vaccine manufacturers, which had previously confirmed the effectiveness of their drugs against new mutations from Corona.

Alexander Ginsberg, director of the (Gamalia) Research Center in Moscow, said: “Our studies show good results for the effectiveness of the “Sputnik V” vaccine against new strains of the emerging coronavirus (Covid 19). We are receiving more and more data about the ability of the coronavirus to transform and transform in all regions. around the world”.

And the director of the center continued: “Today, “Sputnik V” is one of the most effective vaccines against both the parent and new strains of the Corona virus, thanks to a unique approach based on the use of different glandular vectors as delivery tools.
In turn, Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said: “(Sputnik V) was the first vaccine to use different adenoviral vectors during vaccination. The Russian Research Center demonstrated the validity of this approach.”

The Russian Ministry of Health registered the world’s first vaccine against “Covid-19”, last August, which was developed by the Gamalya Center for Epidemiology and Microbiology Research and is being produced jointly with the Russian Fund for Direct Investments.

The results of tests related to the “Sputnik V” vaccine showed an efficacy of more than 90 percent and a high safety rate, as it is given in two doses at an interval of 21 days.